Abstracts tagged "Imaging and giant cell arteritis"

Abstract Number: 2199 • 2018 ACR/ARHP Annual Meeting
Active Disease and Follow up 18f-FDG-PET/CT in Patients with Giant Cell Arteritis. Which Treatment Is More Likely to Achieve Remission?
Verena Schönau¹, Georg Schett², Matthias Englbrecht¹, Juergen Rech³ and Jessica Roth¹, ¹Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany, ²Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Department of Internal Medicine 3 – Rheumatology and Immunology, University Hospital Erlangen, Erlangen, Germany, ³Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany
Background/Purpose: Giant cell arteritis is the most common large vessel vasculitis. 18F-FDG-PET/CT is known to be a useful imaging technique for diagnosing giant cell arteritis.…
Abstract Number: 2200 • 2018 ACR/ARHP Annual Meeting
Does an 18f-FDG-PET/CT in Patients with Giant Cell Arteritis in Clinical Remission Make Sense?
Verena Schönau¹, Jessica Roth¹, Matthias Englbrecht¹, Juergen Rech² and Georg Schett³, ¹Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany, ²Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany, ³Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Department of Internal Medicine 3 – Rheumatology and Immunology, University Hospital Erlangen, Erlangen, Germany
Background/Purpose: Giant cell arteritis is the most common large vessel vasculitis. 18F-FDG-PET/CT is known to be a useful imaging technique for diagnosing giant cell arteritis.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].